Mastering Agitation Endpoints with Assessment Expertise

July 30, 2025

Consistent, high-quality assessments are essential in agitation trials. In this focused case study, see how CRC’s rater services helped one sponsor manage scale complexity and tight timelines without compromising data integrity.


As part of a broader partnership, CRC led rater training, certification, and ongoing surveillance for a Phase III study evaluating a novel treatment for agitation associated with dementia. With 45 raters across 16 sites, consistency and precision were critical to ensure clean, dependable data.


What you'll learn:


  • How CRC designed and delivered a tailored rater training and certification program
  • Approaches used to manage scale complexity and minimize variability
  • The impact of algorithmic surveillance on rater quality and oversight

Need reliable data? Let’s talk.

neural network
September 10, 2025
Why do neuropsychiatric trials fail? Experts Dr. Steve Brannan and Dr. David Walling share strategies to protect investments in neuropsychiatric drug development.
Jason Casarella
September 2, 2025
Experienced CRO executive joins Cognitive Research Corporation to expand partnerships and strengthen its position as a leading CRO for CNS clinical trials
psychedelic mushrooms
August 20, 2025
Psychedelic clinical research is advancing. Explore how trials with psilocybin, LSD, MDMA, and DMT are redefining protocols, standards, and future therapies.
Show More